Intelligent Bio Solutions Inc (INBS), a medical technology company focused on rapid, non-invasive testing solutions, has entered into a strategic manufacturing partnership with Syrma Johari MedTech Ltd to scale production of its Intelligent Fingerprinting Drug Screening Reader and support long-term margin expansion.

Under the agreement, Syrma Johari will serve as a key manufacturing partner for INBS, significantly expanding global production capacity and strengthening supply-chain resilience ahead of the company’s planned entry into the US market in 2026. The collaboration is expected to deliver production cost savings of over 40 percent annually, translating into an estimated improvement of around 20 percentage points in gross margin compared with INBS’ previous manufacturing arrangement.

Syrma Johari’s manufacturing capacity is approximately four times INBS’ current production capability, positioning INBS to efficiently support rising demand as it scales commercial operations across multiple regions. The partnership also reduces reliance on a single supplier, enhancing continuity, flexibility, and long-term operational stability.

With more than 45 years of experience, Syrma Johari brings extensive expertise in the design, engineering, and manufacturing of regulated medical devices. The company operates 14 manufacturing facilities and four design and innovation centres across India, Europe, and the United States, covering more than 1.1 million sq ft of manufacturing space. Its facilities are certified to ISO 13485, MDSAP, FDA, TUV SUD, and GMP standards, supporting compliance with global regulatory requirements.

Syrma Johari’s vertically integrated and export-focused manufacturing model enables efficiencies across sourcing, tooling, testing, and logistics. Its capabilities in electronics manufacturing, mechanical assembly, printed circuit board production, functional testing, and clean-room processes will support consistent, high-quality production of INBS’ drug-screening reader while delivering cost advantages over time. The company is also set to expand its capabilities further with the launch of a new medical-grade plastics manufacturing facility in India in January 2026.

In addition, Syrma Johari’s regulatory and quality systems are aligned with INBS’ global expansion plans, offering end-to-end quality assurance and regulatory documentation support across key markets, including the US, Europe, Canada, the UK, and Asia-Pacific.

“Partnering with Syrma Johari is a strategically significant milestone for our business,” said Callistus Sequeira, vice president of global quality and operations at Intelligent Bio Solutions. “Their global footprint, manufacturing excellence, and proven track record in regulated medical devices make them an ideal partner as we scale production of our Drug Screening Reader and prepare for future growth.”

Pankaj Wadke, head of international sales and business development at Syrma Johari MedTech, said the partnership reflects a strong alignment in innovation and quality. “We are pleased to support Intelligent Bio Solutions in scaling a disruptive, non-invasive drug-screening technology with global potential, leveraging our engineering strength, manufacturing scale, and quality systems.”